QRxPharma Limited
http://www.qrxpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From QRxPharma Limited
Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids
The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.
Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids
The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.
Execs On The Move, July-August 2014
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
REJECTED: Strike 3 for QRxPharma's opioids combo MoxDuo
The FDA for the third time has rejected QRxPharma's application for its morphine/oxycodone combination drug MoxDuo – news that sent shares of the firm tumbling as low as 15.4% on 27 May.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release